Abstract
The Adult Changes in Thought (ACT) study is a longitudinal population-based prospective cohort study of brain aging and incident dementia in the Seattle metropolitan area. Observational studies using autopsies from ACT indicate that dementia is a convergent syndrome that commonly derives from Alzheimer’s disease (AD), microvascular brain injury (mVBI), and Lewy body disease (LBD), and that these diseases have prevalent subclinical forms that also are commonly co-morbid. The existence of subclinical diseases highlights potential opportunities to intervene before the development of clinically apparent impairments. Our observations suggest that some such interventions already may exist to suppress processes of AD (statin therapy) or mVBI (treatment of hypertension). Reduced burden of LBD is associated with cigarette smoking; although smoking is not recommended as an intervention, these exposure data may provide clues to alternative neuroprotective mechanisms. Self reported anti-oxidant supplementation was without apparent effect in this cohort on indices of AD, mVBI, or LBD. Continued observational studies of brain aging will provide further insight into the convergent complexity of the dementia syndrome and its subclinical forms as well as highlight potential interventions that will require validation in clinical trials.
Keywords: Population-based, brain aging, neuropathology, cognitive impairment, hypertension, cortical IL-6 concentration, cerebral cortex
Current Alzheimer Research
Title:Adult Changes in Thought Study: Dementia is an Individually Varying Convergent Syndrome with Prevalent Clinically Silent Diseases that may be Modified by Some Commonly Used Therapeutics
Volume: 9 Issue: 6
Author(s): Thomas J. Montine, Joshua A. Sonnen, Kathleen S. Montine, Paul K. Crane and Eric B. Larson
Affiliation:
Keywords: Population-based, brain aging, neuropathology, cognitive impairment, hypertension, cortical IL-6 concentration, cerebral cortex
Abstract: The Adult Changes in Thought (ACT) study is a longitudinal population-based prospective cohort study of brain aging and incident dementia in the Seattle metropolitan area. Observational studies using autopsies from ACT indicate that dementia is a convergent syndrome that commonly derives from Alzheimer’s disease (AD), microvascular brain injury (mVBI), and Lewy body disease (LBD), and that these diseases have prevalent subclinical forms that also are commonly co-morbid. The existence of subclinical diseases highlights potential opportunities to intervene before the development of clinically apparent impairments. Our observations suggest that some such interventions already may exist to suppress processes of AD (statin therapy) or mVBI (treatment of hypertension). Reduced burden of LBD is associated with cigarette smoking; although smoking is not recommended as an intervention, these exposure data may provide clues to alternative neuroprotective mechanisms. Self reported anti-oxidant supplementation was without apparent effect in this cohort on indices of AD, mVBI, or LBD. Continued observational studies of brain aging will provide further insight into the convergent complexity of the dementia syndrome and its subclinical forms as well as highlight potential interventions that will require validation in clinical trials.
Export Options
About this article
Cite this article as:
J. Montine Thomas, A. Sonnen Joshua, S. Montine Kathleen, K. Crane Paul and B. Larson Eric, Adult Changes in Thought Study: Dementia is an Individually Varying Convergent Syndrome with Prevalent Clinically Silent Diseases that may be Modified by Some Commonly Used Therapeutics, Current Alzheimer Research 2012; 9 (6) . https://dx.doi.org/10.2174/156720512801322555
DOI https://dx.doi.org/10.2174/156720512801322555 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Brain-Skin Connection: Stress, Inflammation and Skin Aging
Inflammation & Allergy - Drug Targets (Discontinued) Diabetes-Related Neurological Implications and Pharmacogenomics
Current Pharmaceutical Design Synthesis and Biological Evaluation of 5,6-Dihydro-benzo[c] acridin-7-ol Derivatives as Anti-Alzheimers Disease Drugs
Letters in Drug Design & Discovery Traumatic Brain Injury as a Risk Factor for Alzheimer’s Disease: Is Inflammatory Signaling a Key Player?
Current Alzheimer Research A Medicinal Mushroom: Phellinus Linteus
Current Medicinal Chemistry β-Amyloid Fibrillation and/or Hyperhomocysteinemia Modify Striatal Patterns of Hyaluronic Acid and Dermatan Sulfate: Possible Role in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Molecular Dynamics and Regulation of Butyrylcholinesterase Cholinergic Activity by RNA Binding Proteins
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Recent Progress in Drug Discovery for Parkinson's Disease)
Current Topics in Medicinal Chemistry Low Levels of High Density Lipoprotein Increase the Severity of Cerebral White Matter Changes:Implications for Prevention and Treatment of Cerebrovascular Diseases
Current Alzheimer Research Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin
CNS & Neurological Disorders - Drug Targets Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Role of Nitric Oxide Synthase Inhibitors in Schizophrenia
Current Medicinal Chemistry NMDA Receptor Antagonists as Antidepressant and Antidementia Drugs: Recent Developments and Future Prospects
Current Medicinal Chemistry - Central Nervous System Agents The Neuroinflammatory Response in Plaques and Amyloid Angiopathy in Alzheimers Disease: Therapeutic Implications
Current Drug Targets - CNS & Neurological Disorders Attentional Set-Shifting in Rodents: A Review of Behavioural Methods and Pharmacological Results
Current Pharmaceutical Design Metal-Protein Attenuating Compounds (MPACs) for the Treatment of Alzheimers Disease
Drug Design Reviews - Online (Discontinued) Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Superior Neuroprotective Effects of Cerebrolysin in Nanoparticle-Induced Exacerbation of Hyperthermia-Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets Green Synthesis of Phosphoryl-2-Oxo-2H-Pyran via Three Component Reaction of Trialkyl Phosphites
Combinatorial Chemistry & High Throughput Screening Protein Aggregation in Alzheimers Disease and Other Neoropathological Disorders
Current Alzheimer Research